Human THRA (Luc) HEK293 Reporter Cell

• Genetically modified cell lines best reflect MOA (Mechanism of Action)
• Higher activity and larger assay window for robust and reproducible cell-based bioassay
• Comprehensive application data to support assay development and validation
• Full tracible record, stringent quality control and validated cell passage stability
• Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
• Global commercial license assistance whenever regulatory filing is required

The Human THRA (Luc) HEK293 Reporter Cell was engineered to not only express thyroid hormone response element (TRE), but also express the receptor full length human THRA (Uniprot: P10827-2), which can drive luciferase expressing systems by thyroid hormone (TH) or thyroid hormone receptor (THR) agonists stimulation. In the absence of TH or THR agonists, the THRA receptor is not activated and luminescence signal is low. In the presence of TH or THR agonists, the THRA pathway-activated luminescence can be detected in a dose-dependent manner.

• Screen for THR-β-selective agonists.

Adherent

Puromycin (2 μg/mL) + Hygromycin B (20 μg/mL)

DMEM + 10% FBS

Serum-free cell cryopreservation medium

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

Frozen in liquid nitrogen.

Negative

Negative

See data sheet for detailed culturing and assay protocol.